Comparative Pharmacology
Head-to-head clinical analysis: CLOPRA YELLOW versus COMPAZINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CLOPRA YELLOW versus COMPAZINE.
CLOPRA-"YELLOW" vs COMPAZINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Clopra (metoclopramide) is a dopamine D2 receptor antagonist and, at higher doses, a serotonin 5-HT4 receptor agonist, which enhances gastrointestinal motility and accelerates gastric emptying. It also has central antiemetic effects via D2 blockade in the chemoreceptor trigger zone.
Dopamine D2 receptor antagonist in the chemoreceptor trigger zone; also blocks alpha-1 adrenergic, histamine H1, and muscarinic M1 receptors.
Adult: 25-50 mg orally 3-4 times daily; maximum 200 mg/day. For severe pain: 50-100 mg intramuscularly every 4-6 hours; maximum 300 mg/day.
5-10 mg IM/IV every 3-4 hours as needed; or 25 mg PO/PR twice daily for severe nausea/vomiting.
None Documented
None Documented
8-12 hours in normal renal function; prolonged to 24-48 hours in severe renal impairment (CrCl <30 mL/min)
Terminal elimination half-life is approximately 23 hours (range 15-30 hours) after oral or intramuscular administration. Clinical context: requires multiple daily dosing for steady state.
Renal: 70% unchanged, Biliary/Fecal: 20% as metabolites, 10% other
Renal (approximately 70% as metabolites, <1% unchanged), biliary/fecal (approximately 30%).
Category C
Category C
Antiemetic/Prokinetic Agent
Antipsychotic (Phenothiazine) / Antiemetic